RZLT Rezolute Inc
Company Analysis
Latest News
🟢 Rezolute is trading 5.9% up today following positive FDA feedback on its Phase III program
Rezolute is trading 5.9% up at $5.20 following productive FDA Type B meeting outcomes for its Phase III ersodetug program in congenital hyperinsulinism. • The...
🔴 Rezolute is trading 6.45% down today amid broader biotech sector weakness
Rezolute is trading at $4.57 (-6.45%) amid a sharp intraday selloff, appearing to track broader biotech sector weakness rather than company-specific news. •...
🔴 Rezolute is trading 5.6% down today with no clear company-specific catalyst
Rezolute is trading at $4.71 (-5.61%) in pre-market following a weaker close on July 24, with no fresh company-specific catalysts identified. • The move...
🔴 Rezolute is trading 5.3% down today with no clear company-specific catalyst
Rezolute is trading 5.3% down at $5.03 today with no fresh company-specific catalysts, likely reflecting positioning after a strong move earlier in the...
🟢 Rezolute is trading 5% up today with no clear company-specific catalyst
Rezolute is trading 5% up today at $5.25 despite a lack of fresh company-specific headlines or fundamental catalysts. • No major news, FDA decisions, earnings...
🟢 Rezolute is trading 10.1% up
Rezolute is trading at $4.90, up 10.1% from a comparison close of $4.45 during regular trading. This is a price-action follow-up, so a separate catalyst may...
🟢 Rezolute Inc is trading 6.40% up
RZLT is trading at $4.74, up 6.40%.
Rezolute Downgraded to Strong Sell, Following Volatility in Metabolic Pipeline
Zacks Research downgraded Rezolute Inc. from hold to strong sell on Saturday, July 18. This rating cut signals strong bearish sentiment for the clinical-stage...
🟢 Rezolute is trading 5.4% up today on technical rebound after Phase 3 trial selloff
Rezolute is trading 5.4% up today at $4.61 as investors cautiously buy following an extreme selloff tied to the failed Phase 3 sunRIZE trial for ersodetug in...
🔴 Rezolute is trading 5.4% down today on continued fallout from Phase 3 trial failure
Rezolute is trading at $4.48 (down 5.4%) as investors continue to digest the failed Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism. • The...
🔴 Rezolute Inc is trading 6.44% down in pre-market
RZLT is trading at $4.65, down 6.44% in pre-market.
🔴 RZLT is trading 5% down today extending weakness after Phase 3 trial failure
RZLT is trading at $4.93 (5% down) today, extending its recent decline as negative sentiment persists following the failed Phase 3 trial of its hypoglycemia...
🟢 RZLT is trading 5% up today after positive pipeline updates
RZLT is trading 5% up at $5.14 after recent positive updates on its hyperinsulinism programs. • On June 2, the company reported positive interim data from its...
🟢 Rezolute Inc is trading 5.4% up today as ENDO clinical data fuels multi-day rally
Rezolute Inc is trading 5.4% up today at $5.05, extending a strong multi-day rally from the low-$3 range following positive clinical data presentations. • The...
🟢 Rezolute Inc is trading 5.4% up today on hyperinsulinism data presentations at ENDO
Rezolute Inc is trading 5.4% up at $4.82, extending its recent multi-day rally following positive clinical developments. • The company highlighted four new...
🟢 Rezolute Inc is trading 6.1% up today extending gains after Guggenheim Best Idea call
Rezolute Inc is trading 6.1% up at $4.59, extending a rally sparked by a significant analyst upgrade and positive clinical outlook. • Guggenheim raised its...
Guggenheim Names Rezolute a Best Idea With an $11 Target — But Can a Pre-Revenue Biotech Justify a 147% Implied Upside?
Shares of Rezolute surged 11.3% to $4.45 after Guggenheim analyst Debjit Chattopadhyay raised his price target to $11.00 and designated the stock a "Best Idea"...
🟢 Rezolute Inc Surges 11.3% on Positive Phase 3 upLIFT Study Data and Guggenheim Price Target Boost to $11
Rezolute Inc is trading 11.3% up at $4.45 today, driven by positive interim data from its Phase 3 upLIFT study and a significant price target increase from...
🟢 Rezolute Inc is trading 5% up today after Guggenheim raised its price target
Rezolute Inc is trading 5% up at $4.20 in pre-market. * Guggenheim analyst Debjit Chattopadhyay raised the price target for RZLT to $11.00 on June 15, 2026. *...
🟢 Rezolute Inc is trading 5.2% up today as shares rebound from recent weakness
Rezolute Inc is trading 5.2% up at $4.06 as the stock stages a recovery following recent weakness over the past week. • No fresh company announcements, FDA...